Journal article
Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study
JEC Bromberg, S Issa, K Bakunina, MC Minnema, T Seute, M Durian, G Cull, HC Schouten, WBC Stevens, JM Zijlstra, JW Baars, M Nijland, KD Mason, A Beeker, MJ van den Bent, M Beijert, M Gonzales, D de Jong, JK Doorduijn
Lancet Oncology | ELSEVIER SCIENCE INC | Published : 2019
Abstract
Background: The prognosis for primary CNS lymphoma has improved with the use of high-dose methotrexate-based chemotherapy, but patient outcomes remain poor. Rituximab, a chimeric monoclonal antibody that targets the CD20 cell surface protein, has substantial activity in systemic CD20-positive diffuse large B-cell lymphoma, but its efficacy in primary CNS lymphoma is unknown and low penetration of the large rituximab molecule through the blood–brain barrier could limit its effect. We aimed to investigate the addition of rituximab to a high-dose methotrexate-based chemotherapy regimen in patients with newly diagnosed primary CNS lymphoma. Methods: This intergroup, multicentre, open-label, rand..
View full abstractGrants
Awarded by Roche
Funding Acknowledgements
We thank the members of the data and safety monitoring board-M J B Taphoorn (Leiden University Medical Centre, Leiden, Netherlands), M A Rosenthal (Melbourne, VIC, Australia), and the statistician T Gorlia (European Organisation for Research and Treatment of Cancer, Brussels, Belgium)-for their contribution to the safe conduct of the study. We thank the HOVON Data Centre for overall trial management and central data management and the Australasian Leukaemia and Lymphoma Group for trial management in Australia and New Zealand. We thank Nathalie Hijmering from the HOVON Pathology Facility and Biobank for making the central pathology review possible. We thank the Dutch Cancer Society (grant no KWF [KS 4589]) and the Stichting STOPhersentumoren for financial support of data and trial management and monitoring, and Roche for financial support and providing rituximab free of charge. Finally, we thank all patients and next of kin who were willing to enrol in the study and contribute to the advancement of knowledge regarding this rare disease, and all trial staff at the participating sites.